We are a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its lead product candidate, ONP-002.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$10M
▲ +6.9% YoY
Op. Margin
–
ROIC
-115.51%
▲ +236.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▼ -7.5% YoY
Op. Cash Flow (TTM)
-$10M
▼ -7.5% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with OGEN
Oragenics (OGEN) in three numbers
Questions about Oragenics
Is Oragenics (OGEN) overvalued?
Oragenics trades at 0.33 times earnings. Intrinsiqq's fair value calculator has no opening value for OGEN, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Oragenics a high-quality business?
Oragenics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$4M, and its weakest is return on capital at -115.5%. The Quality tab shows every check against its target.
Does Oragenics (OGEN) pay a dividend?
No. Oragenics (OGEN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in OGEN's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing OGEN
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.